CCPC, one of the large-scale integrated pharmaceutical corporations in Taiwan, has developed and manufactured various pharmaceuticals with a variety of production lines. Hence, we have accumulated many mature technologies and experiences, while establishing unique critical technology platforms.
In addition to the technological know-how to manufacture various drug formulations, we also possess several advanced controlled-release technologies as explained below:
A poorly soluble drug is dispersed evenly in an inert carrier at the solid state as a means of increasing drug solubility, a faster dissolution rate, and improvements on bioavailability and stability of the drug due to the particle size reduction. This technique may overcome the difficulties of low oral bioavailability. The solid dispersed intermediates can be further processed into conventional tablets or capsules.
Using laser perforation and semi-permeable membrane techniques, the active ingredients are continually released through small pores on the tablet surface. Conveniently, the patient needs only to take the drug once or twice a day to maintaining drug concentration for 24 hours.
e.g. Nifecardia® (Nifedipine); Xadosin® (Doxazosin); ADHOOD® (Methylphenidate)；Pardone®( Paliperidone)
The technique of embedding a layered subunit within the tablet makes it possible to release the active ingredients in several instances, maintaining consistent drug levels for a long period.
e.g. Finska LP® (Loratadine / Pseudoephedrine )
Taking advantage of matrix structures composed of pharmaceutical polymer materials, the active ingredients in question can be dispersed throughout the polymer before being compressed into tablet forms. The slow and controlled release of the active ingredients is made possible through this technique. Conveniently, the patient needs only to take the drug once or twice a day to maintaining drug concentration for 24 hours.
e.g. Naposin® (Naproxen); Trenfylline® (Pentoxifylline); Glicron® (Gliclazide); Glibudon® (Metformin)
A pharmaceutical polymer that can only be dissolved in the intestinal tract is applied to the surface of a tablet or the spherical pellets. When the patient takes the enteric-coated tablet or pellets, the active ingredients that are unstable in gastric acid, stimulative to the stomach, or have to be released into the intestine are protected from the stomach. Dissolution and absorption of the active ingredients are delayed until they reach the duodenum or small intestine. This delivery system can prevent patient illness.
e.g. Taquidine® (Lansoprazole)
Numerous small spherical excipients are used as carriers using multiparticulate technology, and after the active ingredients are evenly dispersed or dissolved, they are covered on the surface of the spherical carriers. An additional polymeric microporous membrane is applied to the pellets, then filled into capsules or compressed to tablets. After oral administration, the active ingredients are released through the micropores on the membrane by the peristaltic activity of the gastrointestinal tract.
e.g. Zotan® (Tamsulosin); Rafax® (Venlafaxine)
A multiple-layer tablet consists of a long-acting, immediate-release layer and a slow-release layer. The active ingredients are evenly dispersed over the matrix. After oral administration by the patient, the active ingredients are released slowly. Another application is using the matrix as a bone structure, the active ingredients are dispersed evenly into the matrix, and compressed into tablets. Other active ingredients are coated on the tablets after dispersed evenly or dissolved. After oral administration, the active ingredients in the outer film is released immediately, and the active ingredients inside is released slowly. This technique allows for the release of adequate levels for a long period. Conveniently, the patient needs only to take medicine once or twice a day.
e.g. Setizin-CP ® (Cetirizine/Pseudoephedrine); Vantydin 12® (Fexofenadine/Pseudoephedrine)；Finska LP 24® (Loratadine/Pseudoephedrine)
The drug is designed as a tablet, which is disintegrated immediately in the mouth by the selection of the pharmaceutical materials and the design of the manufacturing process. This dosage form is suitable for both immediate-release and extended-release. It is difficult on the development and scale-up production in order to fulfill the requirements of good taste and drug stability. This model of administration is expected to be beneficial to geriatric and pediatric patients, for treatment of patients when compliance may be difficult (e.g., for psychiatric disorders), and patients who do not always have access to water. An orally disintegrating has become a trend for oral administration, as it has the advantages of patient compliance and the convenience of drug administration.
e.g. Arizole® (Aripiprazole); Zotan® (Tamsulosin); Olan® (Olanzapine)